Lenalidomide versus lenalidomide plus dexamethasone prolonged treatment after second-line lenalidomide plus dexamethasone induction in multiple myeloma

Lund, J; Gruber, A; Lauri, B; Duru, AD; Blimark, C; Swedin, A; Hansson, M; Forsberg, K; Ahlberg, L; Carlsson, C; Waage, A; Gimsing, P; Vangsted, AJ; Frolund, U; Holmberg, E; Gahrton, G; Alici, E; Hardling, M; Mellqvist, UH; Nahi, H

Lund, J (reprint author), Karolinska Univ Hosp, Huddinge R53, S-14186 Stockholm, Sweden.

CANCER MEDICINE, 2018; 7 (6): 2256

Abstract

Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that singl......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索